Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia

Inclusion Criteria: * Patients age 18 years or older to less than 65 years, inclusive (at time of informed consent) * Subjects with a current diagnosis of schizophrenia, as defined by DSM-IV-TR criteria and a history of the illness for at least three years prior to screening (as per subject, family, healthcare provider, or by previous medical records). * Subjects with a stable living environment, as demonstrated by the ability to provide contact information for themselves and/or family/friend(s)/caregiver(s). * Subjects who showed previous response to antipsychotic treatment in the past year. * Subjects who are currently treated with oral or depot antipsychotics other than clozapine or who have had a recent lapse in antipsychotic treatment requiring chronic treatment with antipsychotic medication for stabilization. * Subjects who are experiencing a current acute exacerbation of psychotic symptoms requiring stabilization * Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment. Exclusion Criteria: * Female patients who are breastfeeding or who have a positive pregnancy test (urine) result prior to receiving investigational medicinal product * Patients presenting a first episode of schizophrenia based on the clinical judgment of the investigator * Patients who are diagnosed with a disease other than schizophrenia (schizoaffective disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder, anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on current DSM-IV-TR Axis Ι criteria, or who are diagnosed with a personality disorder (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial) * Subjects experiencing acute depressive symptoms within the past 30 days * Subjects with schizophrenia who are considered resistant/refractory to antipsychotic treatment by history * Subjects with a significant risk of violent behavior; who represent a risk of committing suicide * Subjects with clinically significant tardive dyskinesia * Subjects currently treated with insulin for diabetes.